搜索临床试验以:MBX-8025 50 mg(剂量递增期 1)
总计23个结果
-
CymaBay Therapeutics, Inc.终止
-
Dizal Pharmaceuticals完全的
-
The Lymphoma Academic Research OrganisationFrench Innovative Leukemia Organisation完全的
-
AIO-Studien-gGmbHTaiho Pharmaceutical Co., Ltd.; Nordic Pharma SAS完全的
-
University of PittsburghRoche Pharma AG; Aventis Pharmaceuticals终止
-
Fundación Leucemia y Linfoma, SpainRoche Pharma AG完全的
-
Bagcilar Training and Research Hospital完全的
-
Klinički Bolnički Centar ZagrebUniversity of Zagreb招聘中
-
Memorial Sloan Kettering Cancer CenterBoehringer Ingelheim; National Comprehensive Cancer Network完全的
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)尚未招聘
-
OHSU Knight Cancer InstituteGenentech, Inc.; Oregon Health and Science University撤销解剖学 III 期乳腺癌 AJCC v8 | 复发性卵巢癌 | 解剖学 IV 期乳腺癌 AJCC v8 | 晚期恶性实体瘤 | 晚期胰腺癌 | II 期胰腺癌 AJCC v8 | III 期胰腺癌 AJCC v8 | IV 期胰腺癌 AJCC v8 | 复发性乳腺癌 | 复发性前列腺癌 | 晚期前列腺癌 | 复发性成人软组织肉瘤 | 晚期乳腺癌 | 晚期肉瘤 | III 期卵巢癌 AJCC v8 | IV 期卵巢癌 AJCC v8 | 晚期卵巢癌美国
-
Northwestern UniversityNational Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.主动,不招人弥漫性大 B 细胞淋巴瘤 | 浆母细胞淋巴瘤 | B 细胞淋巴瘤,无法分类,具有介于弥漫性大 B 细胞淋巴瘤和伯基特淋巴瘤之间的特征 | 成人伯基特淋巴瘤 | MYC基因突变美国